These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 4521481)

  • 1. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 2. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
    Schwartz HS
    Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: DNA complexes of daunorubicin (NSC-8215) and adriamycin (NSC-123127).
    Trouet A; de Duve C
    Cancer Chemother Rep; 1975; 59(2 Pt 1):260. PubMed ID: 1149004
    [No Abstract]   [Full Text] [Related]  

  • 5. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
    Schwartz HS; Grindey GB
    Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
    [No Abstract]   [Full Text] [Related]  

  • 7. Another hypothesis concerning the antitumor activity and cardiotoxicity of daunorubicin (NSC-82151) and adriamycin (NSC-123127).
    Wheeler DM
    Cancer Chemother Rep; 1975; 59(2 Pt 1):258-9. PubMed ID: 1149002
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin (NSC-123127) and its analogs.
    Henry DW
    Cancer Chemother Rep 2; 1974 Dec; 4(4):5-9. PubMed ID: 4451911
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.
    Silvestrini R; Lenaz L; Di Fronzo G; Sanfilippo O
    Cancer Res; 1973 Nov; 33(11):2954-8. PubMed ID: 4748447
    [No Abstract]   [Full Text] [Related]  

  • 11. Actinomycin D effects on nucleic acids during tumor regression.
    Schwartz HS; Sodergren JE
    Cancer Res; 1968 Mar; 28(3):445-51. PubMed ID: 5238558
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
    [No Abstract]   [Full Text] [Related]  

  • 13. [Possibility of utilizing lymphatic leukemia L1210 as a first screening model in the primary selection of new antitumor antibiotics].
    Shorin VA; Bazhanov VS
    Antibiotiki; 1974 Aug; 19(8):679-84. PubMed ID: 4455117
    [No Abstract]   [Full Text] [Related]  

  • 14. [Selective tumour chemotherapy using oncobiograms (author's transl)].
    Volm M; Kaufmann M; Wayss K; Goerttler K; Mattern J
    Dtsch Med Wochenschr; 1974 Jan; 99(2):38-43. PubMed ID: 4129485
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
    Mizuno NS; Humphrey EW
    Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
    [No Abstract]   [Full Text] [Related]  

  • 16. [Possibilities and limits of pre-therapeutic neoplasm sensitivity cytostatics tests under short-term conditions].
    Volm M; Kaufmann M; Mattern J; Wayss K
    Schweiz Med Wochenschr; 1975 Jan; 105(3):74-82. PubMed ID: 1121657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
    Dombernowsky P; Nissen NI
    Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
    Meriwether WD; Bachur NR
    Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.